Japan Medical Association Opposes Epadel OTC Switch
This article was originally published in PharmAsia News
Japan Medical Association VP Toshio Nakagawa expressed concern regarding the switch of hyperlipidemia drug Epadel to an OTC drug at a press conference in Tokyo Nov. 21, stating that patients self-medicating for lifestyle-related diseases with no symptoms would be extremely dangerous.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.